AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16760246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health worker outreach program
Number of subjects: 1005
Study 16312927 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuang medicine medicated thread moxibustion
Number of subjects: 72
Study 16312927 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture-moxibustion (control)
Number of subjects: 72
Study 10702451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine (20 mL, 150 mg)
Number of subjects: 56
Study 10702451 — intervention group
Group type: COMPARATOR
Intervention: 0.75% racemic bupivacaine
Number of subjects: 56
Study 10702451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 56
Study 9087976 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline and alpha-tocopherol treatment
Number of subjects: 0
Study 9087976 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving selegiline and alpha-tocopherol)
Number of subjects: 0
Study 8403805 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium channel opener pinacidil
Number of subjects: 5
Study 8403805 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium channel blocker glibenclamide
Number of subjects: 5
Study 8403805 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose loading
Number of subjects: 5
Study 3512068 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTV (telepsychiatry)
Number of subjects: 0
Study 3512068 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interviews (control)
Number of subjects: 0
Study 3288525 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of clavulanate‐potentiated amoxycillin (1200 mg) 2 hours before surgery
Number of subjects: 100
Study 3288525 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefotaxime (2 g each) in three doses during surgery, and 6 and 12 hours after surgery
Number of subjects: 100
Study 31860360 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoached feigning
Number of subjects: 114
Study 31860360 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached feigning
Number of subjects: 114
Study 31860360 — intervention group
Group type: COMPARATOR
Intervention: Honest nonclinical
Number of subjects: 114
Study 31860360 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Impression Management (NIM) scale
Number of subjects: 114
Study 31860360 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering Index
Number of subjects: 114
Study 31486724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tech-supported home-based palliative care (HBPC) model with video consultation
Number of subjects: 10000
Study 31486724 — intervention group
Group type: COMPARATOR
Intervention: Standard home-based palliative care (HBPC) model with routine home visits by nurses and prescribing clinicians
Number of subjects: 10000
Study 31486724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tech-supported home-based palliative care (HBPC) model
Number of subjects: 10000
Study 28751300 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week Internet-based guided self-help program with weekly therapist support via encrypted email
Number of subjects: 58
Study 28751300 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 58
Study 25979219 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 38
Study 25979219 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal approach
Number of subjects: 38
Study 23052541 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg of 20% mannitol 150 min after the initiation of pneumoperitoneum
Number of subjects: 40
Study 23052541 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control group)
Number of subjects: 40
Study 22187187 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet lysate
Number of subjects: 2
Study 22187187 — intervention group
Group type: COMPARATOR
Intervention: Wait and see strategy
Number of subjects: 2
Study 19029316 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg twice daily)
Number of subjects: 25
Study 16436790 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage nurses applying the Ottawa Ankle Rules (OAR) for ordering roentgenograms before physician evaluation.
Number of subjects: 130
Study 16436790 — intervention group
Group type: COMPARATOR
Intervention: Standard departmental care (control).
Number of subjects: 130
Study 16436790 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage nurses applying the OAR.
Number of subjects: 130
Study 16436790 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction ratings.
Number of subjects: 130
Study 16436790 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to return for future care (WOR).
Number of subjects: 130
Study 11986440 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent conferences (ICCs) including the child-patient
Number of subjects: 14
Study 10647358 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGN guideline plus a formal training programme
Number of subjects: 2700000
Study 10647358 — intervention group
Group type: COMPARATOR
Intervention: SIGN guidelines alone
Number of subjects: 2700000
Study 7669307 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration with 40 ml of bupivacaine 0.5% (pH 6.9) 15 minutes prior to incision
Number of subjects: 56
Study 7669307 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with bupivacaine at the end of surgery
Number of subjects: 56
Study 7669307 — intervention group
Group type: COMPARATOR
Intervention: No local anesthetic infiltration (control group)
Number of subjects: 56
Study 2073336 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐SOD 500 units/kg
Number of subjects: 12
Study 2073336 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐SOD 1000 units/kg
Number of subjects: 12
Study 2073336 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated)
Number of subjects: 12
Study 7031014 — intervention group
Group type: EXPERIMENTAL
Intervention: Halsted mastectomy
Number of subjects: 701
Study 7031014 — intervention group
Group type: COMPARATOR
Intervention: Quadrantectomy
Number of subjects: 701
Study 29794530 — intervention group
Group type: EXPERIMENTAL
Intervention: Active somatosensory stimulation
Number of subjects: 55
Study 29794530 — intervention group
Group type: COMPARATOR
Intervention: Sham somatosensory stimulation
Number of subjects: 55
Study 28678940 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating intervention (six counseling sessions on healthy feeding during the child's first year of life)
Number of subjects: 320
Study 28678940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 320
Study 26289588 — intervention group
Group type: EXPERIMENTAL
Intervention: APF530 500 mg
Number of subjects: 0
Study 26289588 — intervention group
Group type: COMPARATOR
Intervention: palonosetron 0.25 mg
Number of subjects: 0
Study 24211000 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based patient-controlled sedation (PCS), 15mg bolus in 9 s
Number of subjects: 61
Study 24211000 — intervention group
Group type: COMPARATOR
Intervention: Placebo-based patient-controlled sedation (PCS), bolus of 1.5mL of a 20% lipid emulsion in 9 s
Number of subjects: 61
Study 24211000 — intervention group
Group type: COMPARATOR
Intervention: Placebo-based patient-controlled sedation (PCS)
Number of subjects: 61
Study 24211000 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based patient-controlled sedation (PCS)
Number of subjects: 61
Study 21168853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 38
Study 18433946 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen
Number of subjects: 54
Study 18433946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 16968847 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait-and-see prescription (WASP)
Number of subjects: 283
Study 16968847 — intervention group
Group type: COMPARATOR
Intervention: Standard prescription (SP)
Number of subjects: 283
Study 14513232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin (GC)
Number of subjects: 70
Study 14513232 — intervention group
Group type: COMPARATOR
Intervention: MVAC
Number of subjects: 70
Study 11320561 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA B-18 frequency in patients with sarcoidosis
Number of subjects: 88
Study 11320561 — intervention group
Group type: COMPARATOR
Intervention: HLA-DR1 presence in stage IV patients
Number of subjects: 88
Study 11320561 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A class I frequency
Number of subjects: 88
Study 8776948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer
Number of subjects: 0
Study 8776948 — intervention group
Group type: COMPARATOR
Intervention: Compressed air nebulizer
Number of subjects: 0
Study 1513609 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (15 mg/kg/day in two divided doses)
Number of subjects: 214
Study 1513609 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (20 mg/kg/day in three divided doses)
Number of subjects: 214
Study 6402915 — intervention group
Group type: EXPERIMENTAL
Intervention: Drip coffee
Number of subjects: 0
Study 6402915 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant coffee
Number of subjects: 0
Study 6402915 — intervention group
Group type: EXPERIMENTAL
Intervention: Double strength instant coffee
Number of subjects: 0
Study 6402915 — intervention group
Group type: COMPARATOR
Intervention: Coffee consumed 1 hour before a meal
Number of subjects: 0
Study 6402915 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumed 1 hour after a meal
Number of subjects: 0
Study 6402915 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee with NaFeEDTA
Number of subjects: 0
Study 30732198 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT) application to the quadriceps and gastrocnemius muscles
Number of subjects: 25
Study 30732198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 29357912 — intervention group
Group type: EXPERIMENTAL
Intervention: eRegistry's interactive checklists and clinical decision support
Number of subjects: 7200
Study 29357912 — intervention group
Group type: COMPARATOR
Intervention: Existing paper-based records
Number of subjects: 7200
Study 27605494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (n = 30)
Number of subjects: 59
Study 27605494 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n = 29)
Number of subjects: 59
Study 25203150 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI staple diet
Number of subjects: 140
Study 25203150 — intervention group
Group type: COMPARATOR
Intervention: Normal diabetic diet control
Number of subjects: 140
Study 24060022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented HA
Number of subjects: 60
Study 24060022 — intervention group
Group type: COMPARATOR
Intervention: Cementless HA
Number of subjects: 60
Study 20836608 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention
Number of subjects: 0
Study 20836608 — intervention group
Group type: COMPARATOR
Intervention: Self-efficacy
Number of subjects: 0
Study 20836608 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study 18753749 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations without leakage (L-) with fluoride dentifrice (FD)
Number of subjects: 14
Study 18753749 — intervention group
Group type: COMPARATOR
Intervention: Restorations with leakage (L+)
Number of subjects: 14
Study 18753749 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations with composite resin (CR) under non-fluoride dentifrice (NF)
Number of subjects: 14
Study 18753749 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations with resin-modified glass ionomer cement (GI)
Number of subjects: 14
Study 16054266 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 753
Study 16054266 — intervention group
Group type: COMPARATOR
Intervention: Human soluble insulin
Number of subjects: 753
Study 12492754 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention (treatment as usual plus a one-session brief motivational intervention)
Number of subjects: 151
Study 12492754 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 151
Study 12492754 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 151
Study 11345028 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of Ukrain
Number of subjects: 75
Study 11345028 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of Ukrain
Number of subjects: 75
Study 11345028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Ukrain treatment)
Number of subjects: 75
Study 8940324 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (0.7 g/kg) in women on ERT
Number of subjects: 24
Study 8940324 — intervention group
Group type: COMPARATOR
Intervention: Placebo in women on ERT
Number of subjects: 24
Study 8940324 — intervention group
Group type: COMPARATOR
Intervention: Alcohol ingestion (0.7 g/kg) in control women not on ERT
Number of subjects: 24
Study 8940324 — intervention group
Group type: COMPARATOR
Intervention: Placebo in control women not on ERT
Number of subjects: 24
Study 1286442 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey
Number of subjects: 60
Study 1286442 — intervention group
Group type: COMPARATOR
Intervention: Site visit (gold standard)
Number of subjects: 60
Study 2864936 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine pivalate (K 30 052, Ep)
Number of subjects: 0
Study 2864936 — intervention group
Group type: COMPARATOR
Intervention: Etilefrine
Number of subjects: 0
Study 30520271 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention
Number of subjects: 38
Study 30520271 — intervention group
Group type: COMPARATOR
Intervention: Typical instruction
Number of subjects: 38
Study 30239207 — intervention group
Group type: EXPERIMENTAL
Intervention: Method to search for patterns and groupings of patterns in protein sequences
Number of subjects: 0
Study 26079918 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel 3D stereoscopic viewer
Number of subjects: 40
Study 26079918 — intervention group
Group type: COMPARATOR
Intervention: Traditional stereoendoscope
Number of subjects: 40
Study 26079918 — intervention group
Group type: COMPARATOR
Intervention: 2D high-definition monitors
Number of subjects: 40
Study 26079918 — intervention group
Group type: COMPARATOR
Intervention: 3D high-definition monitors
Number of subjects: 40
Study 24818590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Prednisolone in addition to low dose aspirin and heparin
Number of subjects: 160
Study 24818590 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to low dose aspirin and heparin
Number of subjects: 160
Study 24818590 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Prednisolone and Placebo)
Number of subjects: 160
Study 23182016 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-light treatment (n = 10)
Number of subjects: 20
Study 23182016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study 19684422 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 15
Study 19684422 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry (MP)
Number of subjects: 15
Study 18316154 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 20% CO2-enriched air as unconditioned stimulus (US) during acquisition trials.
Number of subjects: 55
Study 18316154 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned odor cues (CSs) - diluted ammonia and butyric acid.
Number of subjects: 55
Study 15969861 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 375
Study 15969861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 12055112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% escin gel
Number of subjects: 158
Study 12055112 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% escin gel
Number of subjects: 158
Study 12055112 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 158
Study 10472218 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 1.5 mg kg‐1
Number of subjects: 335
Study 10472218 — intervention group
Group type: COMPARATOR
Intervention: succinylcholine 1 mg kg‐1
Number of subjects: 335
Study 7924784 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 21
Study 3155316 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6 mg oral nitroglycerin three times daily for 2 weeks
Number of subjects: 19
Study 3155316 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg oral nitroglycerin three times daily for 2 weeks
Number of subjects: 19
Study 3155316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29452684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin (two 17 mg tablets daily)
Number of subjects: 181
Study 29452684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 29452684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 181
Study 28194529 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (SGA)
Number of subjects: 144
Study 28194529 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 144
Study 24159051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session targeted metacognitive training programme (n = 14)
Number of subjects: 28
Study 24159051 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 14)
Number of subjects: 28
Study 22694321 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 15
Study 22694321 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaler/curette (control)
Number of subjects: 15
Study 22694321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 15
Study 20039090 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) algorithm-guided antibiotic therapy
Number of subjects: 0
Study 17905660 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 29
Study 17905660 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa plus add-back therapy (progestagen, tibolone, combined oestrogen and progestagen, or raloxifene)
Number of subjects: 29
Study 17905660 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa (given for at least 3 months before surgery)
Number of subjects: 29
Study 17905660 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 29
Study 17905660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mifepristone
Number of subjects: 29
Study 17905660 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisinil
Number of subjects: 29
Study 15733250 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more treatment sessions of cognitive-behaviour therapy (CBT)
Number of subjects: 214
Study 12560443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 100 micro g/kg (single subcutaneous injection)
Number of subjects: 66
Study 12560443 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim 5 micro g/kg (daily subcutaneous injections)
Number of subjects: 66
Study 10364416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 set of arm-curl training (80% 1-RM)
Number of subjects: 8
Study 10364416 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets of arm-curl training (80% 1-RM)
Number of subjects: 8
Study 8818089 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice porridge feeding 5 hours 30 minutes before anesthesia induction
Number of subjects: 20
Study 8818089 — intervention group
Group type: COMPARATOR
Intervention: Fasted group (control) allowed solid food until midnight before surgery
Number of subjects: 20
Study 8818089 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice porridge feeding
Number of subjects: 20
Study 8818089 — intervention group
Group type: COMPARATOR
Intervention: Fasted group (control)
Number of subjects: 20
Study 1441876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 117
Study 1441876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 117
Study 1441876 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 117
Study 6588473 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine, 0.4 micrograms/kg/min
Number of subjects: 44
Study 6588473 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenaline, 2 micrograms/kg/min
Number of subjects: 44
Study 6588473 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine, 50 micrograms/kg/min
Number of subjects: 44
Study 6588473 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 10 micrograms/kg/min
Number of subjects: 44
Study 6588473 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 44
Study 31445316 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (2.5 g/d for 45 days)
Number of subjects: 40
Study 31445316 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 40
Study 30115598 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (up to 800 mg/day) for 4 weeks
Number of subjects: 481
Study 30115598 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (≤20 mg/day) for 6 weeks
Number of subjects: 481
Study 30115598 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride for 6 weeks
Number of subjects: 481
Study 30115598 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (≤900 mg/day) for 12 weeks
Number of subjects: 481
Study 27103795 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 μg
Number of subjects: 1017
Study 27103795 — intervention group
Group type: COMPARATOR
Intervention: TIO 18 μg
Number of subjects: 1017
Study 24568323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 50
Study 24568323 — intervention group
Group type: COMPARATOR
Intervention: Medications for pain relief
Number of subjects: 50
Study 22291116 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP with heliox (80% helium and 20% oxygen)
Number of subjects: 51